Access
To read this story in full you will need to login or make a payment (see right).
Business
Nature 443, 897 (26 October 2006) | doi:10.1038/443897a; Published online 25 October 2006
Open Innovation Challenges
-
Direct Molecular Detection of Proteins and Nucleic Acids
This Challenge is looking for novel approaches to protein and nucleic acid detection. This is an Id...
-
Single-cell Analysis Platform
This Challenge is looking for novel approaches to analyzing changes at a single-cell level. This is...
- More Challenges
- Powered by:
nature jobs
Cardiovascular Electrophysiologist / Pharmacologist - GlaxoSmithKline
- GlaxoSmithKline
- Ware, Harlow - United Kingdom
Research Group Leader
- University of Vienna
- Vienna, Austria
Capital gains
Abstract
London is seeking to compete with the Nasdaq as the preferred global venue for science-based companies trying to raise cash. Andrea Chipman reports.
When James Karis needed to raise funds last summer for his company Entelos, based in Foster City, California, he ended up looking far afield. Entelos, which builds computer models of disease for clients in the drug industry, raised the money through an initial public offering on London's Alternative Investment Market (AIM).
To read this story in full you will need to login or make a payment (see right).
